AUROPHARMA2024-10-012024-12-31 AUROPHARMA2024-10-012024-12-31 AUROPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses01Member AUROPHARMA2024-10-012024-12-31in-bse-fin:OneOperatingExpenses02Member AUROPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses01Member AUROPHARMA2024-10-012024-12-31in-bse-fin:FourOperatingExpenses02Member AUROPHARMA2024-12-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 524804 AUROPHARMA NOTLISTED Aurobindo Pharma Limited Equity 2024-04-01 2025-03-31 2025-02-06 2025-01-17 INR Millions Third quarter 16:30:00 18:45:00 2025-02-06 2025-02-06 Not applicable Single segment Pharmaceutical Products 2024-10-01 2024-12-31 Unaudited Standalone 29166300000.00 542600000.00 29708900000.00 15065900000.00 190600000.00 -613700000.00 2651500000.00 661900000.00 682800000.00 4740500000.00 23379500000.00 6329400000.00 0.00 6329400000.00 1640300000.00 -31400000.00 1608900000.00 0.00 4720500000.00 0.00 0.00 0.00 0.00 4720500000.00 -14500000.00 4706000000.00 4706000000.00 0.00 580800000.00 1 8.13 8.13 0.00 0.00 8.13 8.13 NOTES: 1.The above unaudited standalone financial results of Aurobindo Pharma Limited ( the Company ) has been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ( the Act ), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. 2.The above unaudited standalone financial results of the Company as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on February 6, 2025. The results for the quarter and nine months ended December 31, 2024 has been reviewed by the statutory auditors of the Company. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter and nine months ended December 31, 2024. 3.The Company operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, Operating Segment . 4.The Company transferred certain Active Pharmaceutical Ingredients (API) business units to its wholly owned subsidiary, Apitoria Pharma Private Limited (formerly known as Auro Pharma India Private Limited) (APPL) on a going concern basis by way of slump sale with effect from October 1, 2023. Accordingly, disclosures as required under Indian Accounting Standard (Ind AS) 105 Non-Current Assets Held for Sale and Discontinued Operations , in the standalone financial results for all the periods have been suitably presented. Key financials information of discontinued operations: Rs. in million Particulars Quarter Nine months Year ended ended ended 31.12.2024 30.09.2024 31.12.2023 31.12.2024 31.12.2023 31.03.2024 Total Income - - - - 24,183.5 24,183.5 Total expenses - - - - 23,458.6 23,458.6 Profit before tax - - - - 724.9 724.9 Total tax expense - - - - 184.5 184.5 Net profit for the period- - - - 540.4 540.4 Single segment 2024-04-01 2024-12-31 Unaudited Standalone 82013100000.00 2141400000.00 84154500000.00 42495100000.00 488200000.00 -1281800000.00 7899600000.00 1689500000.00 2033200000.00 12801400000.00 66125200000.00 18029300000.00 0.00 18029300000.00 4721200000.00 -78100000.00 4643100000.00 0.00 13386200000.00 0.00 0.00 0.00 0.00 13386200000.00 -43500000.00 13342700000.00 13342700000.00 0.00 580800000.00 1 22.94 22.94 0.00 0.00 22.94 22.94 Foreign Exchange loss 281000000.00 Other Expenses 4459500000.00 Foreign Exchange loss 0.00 Other Expenses 12801400000.00 Notes continue....... 5.The Composite Scheme of Amalgamation under Sections 230 - 232 and other applicable provisions of the Companies Act, 2013 for amalgamation of Mviyes Pharma Ventures Private Limited (“Mviyes”) and Auronext Pharma Private Limited (“Auronext”) (together referred to as ‘Amalgamating Companies’) with the Company ('the Scheme') was sanctioned by Hon'ble National Company Law Tribunal (NCLT) Hyderabad bench vide order dated April 29, 2024. The Scheme has become effective on May 17, 2024 upon filing of the certified copy of the orders passed by NCLT with the relevant Registrar of Companies. In terms of the Scheme, all the assets, liabilities, reserves and surplus of the Amalgamating Companies have been transferred to and vested in the Company. The amalgamation has been accounted under the 'pooling of interests' method in accordance with Appendix C of Indian Accounting Standard ('Ind AS') 103 'Business Combinations'. Accordingly, comparatives have been restated to give effect of the amalgamation in the previous year. 6.The Board of Directors at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of Re. 1 each (representing 0.88% of the total number of equity share shares of the Company) for an aggregate value not exceeding Rs. 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of Rs. 1,460/- per equity share. Upon completion of the buyback, the Company extinguished the equity shares in compliance with applicable rules and regulations. Consequently, the paid up equity share capital was reduced by Rs. 5.1 million. The aggregate amount paid for buyback was Rs. 9,302.4 million including tax and related expenses. -19400000.00 -58200000.00 -4900000.00 -14700000.00 0.00 0.00